Ondansetron orally disintegrating tablets are the generic version of GlaxoSmithKline's Zofran tablets, which had US sales of approximately $314 million for the same strengths for the 12-month period ending December 31, 2006, according to IMS Health.
Zofran is designed to treat nausea and vomiting in as a result of chemotherapy or surgery. The tentative approval covers the drug in 4mg and 8mg strengths.